107 related articles for article (PubMed ID: 11685430)
1. Effects of intranasal salmon calcitonin in juvenile idiopathic arthritis: an observational study.
Siamopoulou A; Challa A; Kapoglou P; Cholevas V; Mavridis AK; Lapatsanis PD
Calcif Tissue Int; 2001 Jul; 69(1):25-30. PubMed ID: 11685430
[TBL] [Abstract][Full Text] [Related]
2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
3. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
4. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
5. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
6. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
7. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
9. Salmon calcitonin in the prevention of bone loss at perimenopause.
Arnala I; Saastamoinen J; Alhava EM
Bone; 1996 Jun; 18(6):629-32. PubMed ID: 8806006
[TBL] [Abstract][Full Text] [Related]
10. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K
Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
[TBL] [Abstract][Full Text] [Related]
11. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
[TBL] [Abstract][Full Text] [Related]
12. A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin.
Overgaard K; Christiansen C
Calcif Tissue Int; 1996 Jul; 59(1):12-6. PubMed ID: 8661977
[TBL] [Abstract][Full Text] [Related]
13. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
14. Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.
Gonnelli S; Cepollaro C; Montomoli M; Gennari L; Montagnani A; Palmieri R; Gennari C
Clin Endocrinol (Oxf); 1997 Jan; 46(1):55-61. PubMed ID: 9059558
[TBL] [Abstract][Full Text] [Related]
15. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment.
Kraenzlin ME; Seibel MJ; Trechsel U; Boerlin V; Azria M; Kraenzlin CA; Haas HG
Calcif Tissue Int; 1996 Apr; 58(4):216-20. PubMed ID: 8661950
[TBL] [Abstract][Full Text] [Related]
16. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
17. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate.
Bianda T; Linka A; Junga G; Brunner H; Steinert H; Kiowski W; Schmid C
Calcif Tissue Int; 2000 Aug; 67(2):116-21. PubMed ID: 10920215
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of nasal salmon calcitonin on calcium and bone metabolism.
Thamsborg G; Skousgaard SG; Daugaard H; Schifter S; Kollerup G; Sørensen OH
Calcif Tissue Int; 1993 Oct; 53(4):232-6. PubMed ID: 8275350
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral density and turnover in non-corticosteroid treated African American children with juvenile rheumatoid arthritis.
Head AJ; Myers LK; Watsky MA; Greenwell MW; Barrow KD; Michelson JA; Carbone LD
J Rheumatol; 2006 May; 33(5):1001-3. PubMed ID: 16652430
[TBL] [Abstract][Full Text] [Related]
20. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
Ellerington MC; Hillard TC; Whitcroft SI; Marsh MS; Lees B; Banks LM; Whitehead MI; Stevenson JC
Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
